View All

Gilead/Kite's Yescarta; Roche discards Tecentriq for bladder cancer
Overwhelming success of Gilead/Kite’s Yescarta; Ridgeback/ Merck in the COVID-19 game; AnaptysBio’s antibody-drug failure; Roche discards Tecentriq for bladder cancer

Gilead's Kite Receives Expanded Approval for its CAR-T Yescarta's in Follicular Lymphoma  Gilead’s Kite has successfully secured success in launching the first-ever chimeric antigen receptor (CAR) T-cell therapy in the Follicular Lymphoma Market. The US FDA approved the Yescarta for adults with relapsed or ...

Find More

Peanut allergy
FDA is reviewing a dangerous way to treat Peanut Allergy

Peanut allergies (PA) are the most common and severe type of food allergies in children. Even a small fragment of this legume to an allergic person can result in permanent brain damage.  The prevalence rate of the Peanut allergy, over the past two decades, has tripled. According to DelveInsight, total prevalen...

Find More

transthyretin amyloidosis

The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...

Find More